Clinical Trials Logo

Opiod Use Disorder clinical trials

View clinical trials related to Opiod Use Disorder.

Filter by:
  • None
  • Page 1

NCT ID: NCT05304364 Completed - Opiod Use Disorder Clinical Trials

Safety, Tolerability, and Pharmacokinetics of Naltrexone Implant (DLP-160)

Start date: March 22, 2022
Phase: Phase 1
Study type: Interventional

This is an Open-Label Study in Healthy Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics of Switching from Oral Naltrexone HCL to DLP-160 (Naltrexone implant) to Intramuscular Vivitrol®

NCT ID: NCT05064826 Recruiting - Opiod Use Disorder Clinical Trials

ED Observation for Opioid Use Disorder

Start date: April 21, 2022
Phase: Early Phase 1
Study type: Interventional

This is a multicenter, randomized clinical comparative effectiveness trial (RCT) in which patients with untreated OUD presenting to a Northwell Health Emergency Department (ED), NYULH-Brooklyn, NYULH-Tisch, and Bellevue Hospital will be randomized (1:1) to be managed clinically through either a standard ED visit or an extended visit through ED observation (EDOU).

NCT ID: NCT03831971 Completed - Opiod Use Disorder Clinical Trials

The Influence of ANS-6637 on Midazolam Pharmacokinetics in Healthy Volunteers

Start date: March 1, 2019
Phase: Phase 1
Study type: Interventional

Background: Opioids are medicines that control pain. But they are often misused, which can lead to illness and death. Opioids increase dopamine to the brain, which makes people feel good and often causes them to crave drugs, leading to misuse and addiction. An investigational drug ANS-6637 may lower the dopamine surge and stop opioid craving. Midazolam is a drug approved for anxiety. Researchers want to give the two drugs together and see if ANS-6637 affects midazolam levels, to help understand how ANS-6637 is used in the body. Objective: To study the safety, tolerability, and effects of ANS-6637 taken with and without midazolam. Eligibility: Healthy adults 18 65 years old Design: Participants will be screened with a medical history, physical exam, and blood and heart tests. Participants who can get pregnant will have a pregnancy test. Participants must agree to use 2 types of birth control during the study, if applicable. Participants will stay at the clinic for 10 days. Meals will be provided. Participants will not be allowed to: Leave NIH campus Eat or drink anything with caffeine, alcohol, or certain juices Use any nicotine or related products (including vaping) Use any medicines (including herbal) During the clinic stay, participants will: Fast overnight several times Have blood drawn most days. Twice, a small tube will be inserted in an arm vein for frequent blood samples. Repeat screening tests and answer questions about their mood several times Get midazolam syrup in water on 1 day Take 6 ANS-6637 tablets by mouth on 5 days Take both study drugs on 1 day A few days later, participants will have a follow-up visit to repeat screening tests and answer questions about their mood.